Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Myriad Genetics was founded in 1991, 10 years before the human genome was sequenced, making Myriad one of the first genomics companies in history.
In 1996, Myriad introduced the first genetic test to assess risk of hereditary breast and ovarian cancer.
In September 2001, Myriad provided genotyping assistance to the New York City Coroner’s Office to help identify the victims of the 9/11 attacks and bring closure to their families.
Beginning in 2001, Myriad sequenced the rice genome, which revealed ways to increase crop yields, decrease pest infestation and potentially improve crop management.
The launch of Prolaris in 2010 provided physicians with the first prognostic test that offers a direct measure of the molecular biology of an individual patient’s prostate cancer.
In 2012, Myriad expanded internationally with the opening of our laboratory in Munich, Germany.
In 2013, Myriad launched MyRisk Hereditary Cancer, a multi-gene panel that identifies an elevated risk for eight hereditary cancers.
Myriad continued its pioneering work in personalized medicine with the launch of BRACAnalysis CDx in 2014.
Rate how well Myriad Genetics lives up to its initial vision.
Do you work at Myriad Genetics?
Is Myriad Genetics' vision a big part of strategic planning?
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Sarepta Therapeutics | 1980 | $1.9B | 840 | 24 |
| Alnylam Pharmaceuticals | 2002 | $2.2B | 1,323 | 1 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 597 |
| Seagen | 1997 | $2.0B | 900 | - |
| ZymoGenetics | 1981 | $27.0M | 200 | - |
| Exelixis | 1994 | $2.2B | 484 | 156 |
| GlobeImmune | 1995 | $6.5M | 22 | - |
| Neurocrine Biosciences | 1992 | $2.4B | 400 | 455 |
| Geron | 1990 | $77.0M | 15 | - |
| Ligand Pharmaceuticals | 1987 | $241.5M | 116 | - |
Zippia gives an in-depth look into the details of Myriad Genetics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Myriad Genetics. The employee data is based on information from people who have self-reported their past or current employments at Myriad Genetics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Myriad Genetics. The data presented on this page does not represent the view of Myriad Genetics and its employees or that of Zippia.
Myriad Genetics may also be known as or be related to MYRIAD GENETICS INC, Myriad Genetics, Myriad Genetics Inc, Myriad Genetics Inc. and Myriad Genetics, Inc.